RP-HPLC raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-04-03. Anything still debated is marked as such rather than presented as settled.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical lyophilized research form. |
| Solubility | Soluble in DMSO; limited in water | Depends on purity and salt form. |
| Storage temperature | -20 °C or lower | Desiccated and protected from light. |
| Analytical method | RP-HPLC and LC-MS | Common for purity and identity. |
| Regulatory status | Research chemical in many countries | Not widely approved as a medicine. |
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
The mtFAS pathway takes place in the mitochondrial matrix and consists of at least six separate enzymes, each encoded by its own gene. This sets it apart from cytosolic fatty acid synthesis, where the multifunctional enzyme fatty acid synthase (FASN) contains all enzymatic activities within a single polypeptide chain and is encoded by a single gene. Despite this structural difference, mtFAS and cytosolic fatty acid synthesis use the same chemistry to build fatty acids. The mitochondrial acyl carrier protein (mtACP) serves as a scaffold for fatty acyl chains but requires prior phosphopantetheinylation by AASDHPPT to convert it from the inactive apo to the active holo form. This activation represents the first step of mtFAS and introduces a 4'-phosphopantetheine group, which provides the thiol group to which the fatty acyl chain is covalently attached and subsequently elongated, while also functioning as a flexible swinging arm. This allows the fatty acyl chain to swing out of its hydrophobic pocket within mtACP and enter those of interacting proteins. Malonyl-CoA provides the substrate for mtFAS and is generated in mitochondria from acetyl-CoA by mtACC1 (a mitochondrial isoform of acetyl-CoA carboxylase 1) and from malonate by acyl-CoA synthetase family member 3 (ACSF3). However, the precise mitochondrial source of malonyl-CoA remains under debate. The malonyl group is transferred from malonyl-CoA to mtACP by malonyl-CoA:ACP transacylase (MCAT), forming malonyl-mtACP.
The Rockefeller Foundation is an American private foundation and philanthropic medical research and arts funding organization based at 420 Fifth Avenue, New York City. The foundation was created by Standard Oil magnate John D. Rockefeller ("Senior") and son "Junior", and their primary business advisor, Frederick Taylor Gates, on May 14, 1913, when its charter was granted by New York. It is the second-oldest major philanthropic institution in America (after the Carnegie Corporation) and ranks as the 35th largest foundation globally by endowment, with assets of over $6.4 billion in 2023. The Rockefeller Foundation is legally independent from other Rockefeller entities, including the Rockefeller University and Rockefeller Center. The foundation operates under the oversight of its own independent board of trustees, with its own resources and distinct mission. Since its inception, the foundation has donated billions of dollars to various causes, becoming the largest philanthropic enterprise in the world by the 1920s. The foundation has maintained an international reach since the 1930s and major influence on global non-governmental organizations. The World Health Organization is modeled on the International Health Division of the foundation, which sent doctors abroad to study and treat human subjects. The National Science Foundation and National Institute of Health are also modeled on the work funded by Rockefeller. It has also been a supporter of and influence on the United Nations.
Glossary of cellular and molecular biology (0–L) lists terms beginning with numbers and those beginning with the letters A through L. Glossary of cellular and molecular biology (M–Z) (this page) lists terms beginning with the letters M through Z. This glossary is intended as introductory material for novices (for more specific and technical detail, see the article corresponding to each term). It has been designed as a companion to Glossary of genetics and evolutionary biology, which contains many overlapping and related terms; other related glossaries include Glossary of virology and Glossary of chemistry.
The country had a 2019 Forest Landscape Integrity Index mean score of 5.95/10, ranking it 90th globally out of 172 countries. Some 3,700 plant species have been identified in the country, from which to date 23 have been declared natural monuments, 74 extinct, 39 endangered, 171 vulnerable, and 1,253 rare. The fauna of Romania consists of 33,792 species of animals, 33,085 invertebrate and 707 vertebrate, with almost 400 unique species of mammals, birds, reptiles, and amphibians, including about 50% of Europe's (excluding Russia) brown bears and 20% of its wolves. Romania is often seen by most as having the shape resembling one of a goldfish.
In Ireland, most universities and technological universities are publicly funded but institutionally autonomous rather than directly state-owned. Higher education is provided by universities, technological universities, institutes of technology, colleges of education and specialist institutions. The Higher Education Authority is the statutory agency responsible for allocating exchequer funding to universities, institutes of technology and other higher education institutions. Under the Free Fees Initiative, the state pays undergraduate tuition fees for eligible students, while students are required to pay a student contribution charge. For the 2025/26 academic year, the student contribution charge is €2,500 per year. Independent and private higher education institutions also operate in Ireland. The Royal College of Surgeons in Ireland was authorised to use the title "university" in Ireland in 2019, becoming RCSI University of Medicine and Health Sciences; it describes itself as an independent, not-for-profit university.
Sources: en.wikipedia.org
=== Professional services === He has fulfilled roles in numerous professional organizations, including the Swedish Biochemical Society (secretary 1976–1982); Chairman of the Swedish National Committee on Biochemistry, Royal Swedish Academy of Sciences, 1988–1990; Chairman Scientific Program Committee for the 22nd Meeting of the Federation of European Biochemical Societies, FEBS 1993; editorial boards of the Biochemical Journal, ChemBioChem, Biochimica et Biophysica Acta, Protein Engineering Design and Selection, the Journal of Biological Chemistry. In addition, he has had advisory roles at various companies: Telik Inc.; PanVera Corporation, Pharmacia Biotech; Uniroyal Chemical Company; Biovitrum AB; Maxygen; Vividion; Oxford Biomedical Research, Rochester Hills, Michigan.
Electrochemotherapy is the combined treatment in which injection of a chemotherapeutic drug is followed by application of high-voltage electric pulses locally to the tumor. The treatment enables the chemotherapeutic drugs, which otherwise cannot or hardly go through the membrane of cells (such as bleomycin and cisplatin), to enter the cancer cells. Hence, greater effectiveness of antitumor treatment is achieved. Clinical electrochemotherapy has been successfully used for treatment of cutaneous and subcutaneous tumors irrespective of their histological origin. The method has been reported as safe, simple and highly effective in all reports on clinical use of electrochemotherapy. According to the ESOPE project (European Standard Operating Procedures of Electrochemotherapy), the Standard Operating Procedures (SOP) for electrochemotherapy were prepared, based on the experience of the leading European cancer centres on electrochemotherapy. Recently, new electrochemotherapy modalities have been developed for treatment of internal tumors using surgical procedures, endoscopic routes or percutaneous approaches to gain access to the treatment area.
Their global total production value of $85 billion is split about 60-40 between in-house production in the life-science industry—the products' main consumers—and companies producing them for sale. The latter pursue both a "supply push" strategy, whereby standard products are developed in-house and offered ubiquitously, and a "demand pull" strategy, whereby products or services determined by the customer are provided exclusively on a "one customer / one supplier" basis. The products are mainly used as building blocks for proprietary products. The hardware of the top tier fine chemical companies has become almost identical: the design, lay-out and equipment of the plants and laboratories have become practically the same globally; most chemical reactions performed go back to the days of the dyestuff industry; and numerous regulations determine the way labs and plants must be operated, thereby contributing to the uniformity.
=== Hydrogel cross-linked with polyacrylamide === Marketed as Bulkamid, this material is a synthetic non-particulate hydrogel composed of water and cross-linked polyacrylamide (2.5%). The size of the molecules is large which makes it resistant to migration. Since it is a non particulate homogeneous hydrogel, it is thought to retain elasticity and does not lead to hard tissue fibrosis or cause other significant reaction in the surrounding tissues. It is non-resorbable and non allergenic. In plastic surgery it is marketed as Aquamid. In one publication where it was used for FI, intersphincteric injection site was used via the intersphincteric route. This material has not achieved widespread use.
Sources: en.wikipedia.org
Collagen alpha-1(XIII) chain is a protein that in humans is encoded by the COL13A1 gene. This gene encodes the alpha chain of one of the nonfibrillar collagens. The function of this gene product is not known, however, it has been detected at low levels in all connective tissue-producing cells so it may serve a general function in connective tissues. Unlike most of the collagens, which are secreted into the extracellular matrix, collagen XIII contains a transmembrane domain and the protein has been localized to the plasma membrane. The transcripts for this gene undergo complex and extensive splicing involving at least eight exons. Like other collagens, collagen XIII is a trimer; it is not known whether this trimer is composed of one or more than one alpha chain isomer. A number of alternatively spliced transcript variants have been described, but the full length nature of some of them has not been determined. Collagen XIII belongs to the transmembranous subfamily of collagens, like collagen XVII, XXIII and XXV.
Early work on the study of the chemistry of rutherfordium focused on gas thermochromatography and measurement of relative deposition temperature adsorption curves. The initial work was carried out at Dubna in an attempt to reaffirm their discovery of the element. Recent work is more reliable regarding the identification of the parent rutherfordium radioisotopes. The isotope 261mRf has been used for these studies, though the long-lived 267Rf (produced in the decay chain of 291Lv, 287Fl, and 283Cn) may be advantageous for future experiments. The experiments relied on the expectation that rutherfordium would be a 6d element in group 4 and should therefore form a volatile molecular tetrachloride, that would be tetrahedral in shape. Rutherfordium(IV) chloride is more volatile than its lighter homologue hafnium(IV) chloride (HfCl4) because its bonds are more covalent. A series of experiments confirmed that rutherfordium behaves as a typical member of group 4, forming a tetravalent chloride (RfCl4) and bromide (RfBr4) as well as an oxychloride (RfOCl2). A decreased volatility was observed for RfCl4 when potassium chloride is provided as the solid phase instead of gas, highly indicative of the formation of nonvolatile K2RfCl6 mixed salt.
Deep learning uses several layers of neurons between the network's inputs and outputs. The multiple layers can progressively extract higher-level features from the raw input. For example, in image processing, lower layers may identify edges, while higher layers may identify the concepts relevant to a human such as digits, letters, or faces. Deep learning has been used to improve the performance of programs in subfields of artificial intelligence including computer vision, speech recognition, natural language processing, image classification and others. Deep neural networks and backpropagation had been in development since 1950. Starting in 2012, the speed of deep learning was increased one hundred-fold by switching to GPUs, and there were enormous amounts of data available on the internet (called at the time "big data") as well as curated datasets used for benchmark testing, such as ImageNet. Usage of deep learning increased in 2012–2015 due to these improvements. In 2025, Geoffrey Hinton said that, until the 2010s, "We couldn't do anything very impressive because we didn’t have enough data and we didn't have enough computation."
=== Background === Mogo is a sentient and living planet. When it is desired, its affiliation with the Corps is shown with foliage arranged into a green band, marked with the standard Green Lantern Corps lantern symbol, circling Mogo's equator. In its early appearances, Mogo is not a social Green Lantern and its interactions with the rest of the DC universe are not well documented. It avoids announcing its presence, preferring to represent itself using pseudonymous holograms. In Mogo's first appearance, it is explained that the planet-sized Mogo's gravitational field would wreak havoc on any other planet it would try to "visit", hence Mogo "doesn't socialize". At the same time, Mogo has allowed alien races to live on its surface and has been willing to change its conditions to suit them. When Parallax, possessing Hal Jordan, destroys the power battery on Oa and kills the Guardians, Mogo loses contact with the Green Lantern energy that helped sustain him. Without energy, Mogo loses consciousness and drifts through Sector 1014 until he is discovered by a nomadic alien race, who strip Mogo of his natural resources and pollute his environment. Mogo's body reacts instinctively, creating constructs to hinder the aliens' efforts to exploit his resources. Mogo is finally rescued by Kyle Rayner, who uses his power ring to reawaken him. With the restoration of the Green Lantern Corps, Mogo has taken on the role of a training and recreation planet for his fellow Green Lanterns. Soranik Natu, Kyle Rayner, and other Lanterns have traveled to his sector to ask for his counsel.
The reduction-oxidation sensitive green fluorescent protein (roGFP) is a green fluorescent protein engineered to be sensitive to changes in the local redox environment. roGFPs are used as redox-sensitive biosensors. In 2004, researchers in S. James Remington's lab at the University of Oregon constructed the first roGFPs by introducing two cysteines into the beta barrel structure of GFP. The resulting engineered protein could exist in two different oxidation states (reduced dithiol or oxidized disulfide), each with different fluorescent properties. Originally, members of the Remington lab published six versions of roGFP, termed roGFP1-6 (see more structural details below). Different groups of researchers introduced cysteines at different locations in the GFP molecule, generally finding that cysteines introduced at the amino acid positions 147 and 204 produced the most robust results. roGFPs are often genetically encoded into cells for in-vivo imaging of redox potential. In cells, roGFPs can generally be modified by redox enzymes such as glutaredoxin or thioredoxin. roGFP2 preferentially interacts with glutaredoxins and therefore reports the cellular glutathione redox potential. Various attempts have been made to make roGFPs that are more amenable to live-cell imaging. Most notably, substituting three positively-charged amino acids adjacent to the disulfide in roGFP1 drastically improves the response rate of roGFPs to physiologically relevant changes in redox potential.
Sources: en.wikipedia.org
The lyophilized powder is generally stored at -20 °C or lower, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data may vary by formulation and purity.
Mass spectrometry is commonly used to confirm molecular mass, while RP-HPLC estimates purity. These methods can be combined with amino acid analysis or NMR for further structural confirmation. A certificate of analysis alone does not guarantee independent verification.
Legality depends on the country and the intended use. In many places it is not approved as a drug and may be regulated as a research chemical. Buyers should check local laws and institutional policies before obtaining it.
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.